Rob Brannon
Chief Executive Officer
Replay available
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call
Champions Oncology, Inc. (NASDAQ: CSBR) Q2 2026 earnings conference call, held 2025-12-15. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
David Miller
Chief Financial Officer
Matt Hewitt
Analyst, Craig-Hallam
Richard Buffarin
Private Investor
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Champions Oncology, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.698 Welcome to the Champions Oncology second quarter fiscal year 2026 earnings call. 00:00:05.698 -- 00:00:08.963 At this time, all participants are in a listen-only mode. 00:00:08.963 -- 00:00:12.347 A question and answer session will follow the formal presentation. 00:00:12.347 -- 00:00:15.852 If anyone should require operator assistance during the conference, please press star 00:00:15.852 -- 00:00:21.139 zero on your telephone keypad. Please note, this conference is being recorded. 00:00:21.139 -- 00:00:25.504 I will now turn the conference over to your host, Rob Brannon, Chief Executive Officer. 00:00:25.504 -- 00:00:27.745 You may begin. 00:00:28.718 -- 00:00:33.383 Good afternoon, and thank you for participating in our second quarter fiscal 2026 earnings 00:00:33.383 -- 00:00:36.866 call. I'm joined today by our CFO, David Miller. 00:00:36.866 -- 00:00:41.451 Before we begin, I'll remind you that today's remarks may include forward-looking statements. 00:00:41.451 -- 00:00:45.675 Actual results may differ materially, and more information can be found in our filings 00:00:45.675 -- 00:00:47.617 with the SEC. 00:00:47.617 -- 00:00:51.301 Before we get into the quarter, I want to ground everyone in our three core goals for 00:00:51.301 -- 00:00:54.757 the year. One, deliver year-on-year revenue growth. 00:00:54.757 -- 00:00:59.503 Scaling matters, and we can get margin leverage in our core TOS business as we grow. 00:00:59.503 -- 00:01:04.368 Two, invest in our big growth levers, especially our data platforms, which opens the 00:01:04.368 -- 00:01:07.192 door to more strategic biopharma relationships. 00:01:07.192 -- 00:01:12.438 And three, stay fiscally disciplined. Maintain full-year positive adjusted EBITDA 00:01:12.438 -- 00:01...